Answers are grounded in this paper and cite their sources.
Analysis shows links between gut microbiome and bronchiectasis in 150 participants, indicating potential biomarkers for disease treatment.
The gut-lung axis links dysbiosis of the gut microbiota to bronchiectasis. Gaining knowledge of the metabolic and microbiological changes can help one understand how a disease develops. To investigate at how the metabolome, gut microbiota, and bronchiectasis are related, and to find possible biomarkers for the diagnosis and treatment of disease was the aim of this research. 150 participants' fecal samples (42 Healthy Controls (HC), 48 Stable Patients (SP), and 60 Acute Exacerbation (AE)) were examined using LC-MS-based metabolomics and 16S rRNA sequencing. For statistical analysis, SPSS 19.0 were utilized, along with Pearson's correlation and LDA effect size (LEfSe). Microorganism diversity was reduced in bronchiectasis patients, with firmicutes and Bacteroidetes being less prevalent. There were changes in several metabolic pathways, such as the metabolism of glycerophospholipids, sphingolipids, purines, and tryptophan. Research emphasizes that the pathophysiology of bronchiectasis is influenced by the gut flora. The significance of more longitudinal research is highlighted by the potential diagnostic and therapeutic targets provided by identified microbial and metabolic biomarkers.
No takes yet. Share an insight, caveat, or question.
Alosaimi et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: